 There are 4 treatment groups in the study: ABT-143 capsules 20135 mg, ABT-143 capsules 10135 mg, ABT-143 5135 mg, and simvastatin capsules 40 mg. The primary outcome measure only compares 2 of these groups: ABT-143 capsules 20135 mg and the simvastatin capsules 40 mg groups, therefore there are only results for these 2 groups and not all 4 groups for this outcome measure . Secondary outcome measure mean percent change in LDL-C comparing ABT-143 capsules 10135 mg to simvastatin capsules 40 mg only compares these 2 groups: ABT-143 capsules 10135 mg and simvastatin capsules 40 mg, therefore there are only results for these 2 groups and not all 4 groups for this outcome measure. Secondary outcome measure mean percent change in LDL-C comparing ABT-143 capsules 5135 mg to simvastatin capsules 40 mg only compares these 2 groups: ABT-143 capsules 5135 mg and simvastatin capsules 40 mg, therefore there are only results for these 2 groups and not all 4 groups for this outcome measure. For the other pre-specified outcome measures, median percent change in triglycerides from baseline to the final visit and mean percent change in HDL-C from baseline to the final visit for the full analysis sets, all 3 ABT-143 capsules 20135 mg, 10135 mg, and 5135 mg groups were compared to the simvastatin capsules 40 mg group, therefore there are results for all 4 treatment groups for these outcome measures. 